Hormone Refractory Breast Cancer Market 2030 by F. Hoffmann La Roche Ltd,, AstraZeneca,, Bluefish Pharmaceuticals AB,, Boehringer Ingelheim International GmbH, Neopharm Group,, Novartis AG,, Eli Lilly and Company
Hormone refractory breast cancer also known as hormone receptor negative breast cancer is a type of breast cancer that does not respond to hormone therapy which is often used as a treatment for breast cancer that is positive for estrogen ...
0 Comments 0 Shares 58 Views